Induction treatment with monoclonal antibodies for heart transplantation [artículo]
Por: Cortina Romero, José María [Cirugía Cardiovascular]
| Sáenz de la Calzada Campo, Carlos [Cardiología] | Delgado Jiménez, Juan Francisco [Cardiología] | Escribano Subías, Pilar [Cardiología] | Gómez Sánchez, Miguel Ángel [Cardiología] | Renés Carreño, Emilio [Medicina Intensiva] | Ruiz Cano, María José [Cardiología] | Sánchez Sánchez, Violeta [Cardiología] | Vaqueriza Cubillo, David [Cardiología].
Colaborador(es): Servicio de Cardiología | Servicio de Cirugía Cardiovascular | Servicio de Medicina Intensiva.
Editor: Transplantation Reviews, 2011Descripción: 25(1):21-26. Tipo de medio: Recursos en línea: Solicitar documento Resumen: Individualization of induction therapy for heart transplantation (HT) is needed, given that only patients at significant risk for fatal rejection seem to present a favorable risk-benefit ratio. The question whether monoclonal interleukin 2 antagonists or antilymphocyte antibodies should be recommended remains unanswered. As most studies suggest that they have similar efficacy in preventing acute rejection, other variables related to safety or management costs should be taken into account. The cytokine release syndrome, associated with the use of OKT3, complicates management of HT patient. The experience in our center with 2 consecutive cohorts, treated with basiliximab (BAS) and OKT3, respectively, suggests that the use of BAS is associated, in addition to similar immunosuppressive efficacy and better safety profile than OKT3, with simpler patient management during the initial hospital stay, which could be associated with a reduction in posttransplant costs. Because few centers continue to use OKT3 as induction therapy in HT, more studies comparing cost-effectiveness of BAS vs polyclonal antilymphocyte antibodies (ATG) are needed.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC11045 (Navegar estantería) | Disponible |
Formato Vancouver:
Delgado JF, Vaqueriza D, Sánchez V, Escribano P, Ruiz-Cano MJ, Renes E, et al. Induction treatment with monoclonal antibodies for heart transplantation. Transplant Rev (Orlando). 2011;25(1):21-6.
PMID: 21126660
Contiene 45 referencias.
Individualization of induction therapy for heart transplantation (HT) is needed, given that only patients at significant risk for fatal rejection seem to present a favorable risk-benefit ratio. The question whether monoclonal interleukin 2 antagonists or antilymphocyte antibodies should be recommended remains unanswered. As most studies suggest that they have similar efficacy in preventing acute rejection, other variables related to safety or management costs should be taken into account. The cytokine release syndrome, associated with the use of OKT3, complicates management of HT patient. The experience in our center with 2 consecutive cohorts, treated with basiliximab (BAS) and OKT3, respectively, suggests that the use of BAS is associated, in addition to similar immunosuppressive efficacy and better safety profile than OKT3, with simpler patient management during the initial hospital stay, which could be associated with a reduction in posttransplant costs. Because few centers continue to use OKT3 as induction therapy in HT, more studies comparing cost-effectiveness of BAS vs polyclonal antilymphocyte antibodies (ATG) are needed.
No hay comentarios para este ejemplar.